Small molecule drug may prevent chemotherapy resistance
Scientists have discovered a small molecule drug that may stop cancer cells from becoming resistant to chemotherapy. Drug resistance is a major cause of cancer relapse and is responsible for as much as 90% of deaths related to the disease.
The new compound, which was tested in an animal model of melanoma, could make current chemotherapies more powerful. It works by thwarting cancer’s ability to survive, evolve, and adapt to the DNA damage created by traditional chemotherapy drugs like cisplatin.
“Chemotherapies are often effective the first time around, but then the cancers mutate and become resistant to that drug, and the next, and the next,” said senior study co-author Pei Zhou, Ph.D., a professor of biochemistry at Duke University School of Medicine.
“It reminds me of Boggarts, those shapeshifting creatures from Harry Potter that morph from one scary thing to another. The beauty of this approach is that you essentially freeze the Boggart in its current form, so you can kill it off for good.”
The study was published June 6 in Cell.
In their simplest form, cancer cells are normal cells that are growing out of control. Each time these cells divide, the DNA within them must replicate to generate new copies to go inside each new cell. The first chemotherapy drugs were based on the rationale that rapidly growing cancer cells would be more sensitive to damage to their DNA. Drugs like cisplatin are designed to damage DNA, causing the sensitive replication machinery normally tasked with copying each strand to stall. If DNA replication is stalled for too long, cell division halts, and cells die.
The strategy is brutal and effective, even curative in some cases. But long-term, it often fails, as cancer cells figure out a way to proliferate even in the presence of DNA damage.
“The cancer cells often swap out the high fidelity replication machinery, which usually does the copying, with a sloppy replacement that covers up the lesions and moves on,” said Zhou. “As a result, the cells survive, but with mutations in their DNA.”
Because this process, known as translesion synthesis, is a major cause of cancer drug resistance, it has become a major area of study in cancer research. Scientists have identified a key protein involved, named Rev1, and have even disrupted it through genetic means — works done in the laboratories of Graham C. Walker and Michael T. Hemann at MIT, both senior co-authors of this study. However, attempts to do the same with small molecules had never succeeded, presumably because the protein lacked an obvious binding pocket that a potential drug could exploit.
In this study, Zhou and his collaborators at Duke, MIT, and the University of Rhode Island decided to try their luck at finding a small molecule to block or inhibit Rev1. They screened 10,000 small molecule compounds, and were surprised to find that one — a molecule called JH-RE-06 — appeared to do the trick.
The researchers used a technique called x-ray crystallography to visualize the unexpected interactions between Rev1 and JH-RE-06. They found that when Rev1 interacts with JH-RE-06, it pairs up or dimerizes with another copy of itself, creating a binding pocket where there wasn’t one before. When Rev1 is locked up in this dimer, it can no longer help cancer cells survive and attain their shape-shifting powers.
The researchers then tested the new molecule in human cancer cell lines and showed that it enhanced the ability of several forms of chemotherapy to kill cells, while also suppressing their ability to mutate in the presence of DNA-damaging drugs. Finally, they tested it in a mouse model of human melanoma. They found that not only did the tumors stop growing in mice treated with a combination of cisplatin and JH-RE-06, but also that those mice survived longer.
Senior study co-author Jiyong Hong, PhD, a professor of chemistry at Duke, said that they are currently creating versions of JH-RE-06 that have enhanced pharmacologic properties that could make it an even more attractive drug. “This is a great proof of principle that it is possible to target this protein, but we have a lot of work to do to turn this lead compound into a viable candidate that we can take to the clinic.”
The Latest on: Cancer drug resistance
via Google News
The Latest on: Cancer drug resistance
- Resistant starch in your diet can reduce cancer in those at riskon August 2, 2022 at 7:38 pm
Resistant starch may reduce cancer development by changing the bacterial metabolism of bile acids and reducing those types of bile acids that can damage our DNA and eventually cause cancer. However, ...
- A new microfluidic system could keep tabs on cancer treatmenton August 2, 2022 at 5:00 am
A new system developed by Johns Hopkins researchers could monitor drug resistance in elusive cancer cells and open the door for more effective treatment options ...
- IDRx Launches with $122 Million Series A Financing to Treat Cancer with Purpose-Built Precision Combination Therapieson August 2, 2022 at 3:30 am
IDRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming cancer treatment with purpose-built precision combination therapies, launched today with a $122 million oversubscribed ...
- Groundbreaking research by Tayside doctors and scientists could lead to new treatments for ovarian canceron August 2, 2022 at 3:14 am
A team of doctors and scientists in NHS Tayside and the University of Dundee has uncovered important new information about how ovarian cancer cells become resistant ...
- NUS study provides evidence of the cytotoxic effect of black cardamom on lung cancer cellson August 1, 2022 at 6:34 am
The main challenges associated with existing lung cancer drugs are severe side effects and drug resistance. There is hence a constant need to explore new molecules for improving the survival rate and ...
- NUS study: Black cardamom effective against lung cancer cellson July 31, 2022 at 5:00 pm
In Indian Ayurvedic medicine, black cardamom has been used in formulations to treat cancer and lung conditions. A team of NUS researchers studied the scientific basis behind this traditional medicinal ...
- Breakthrough cancer treatment uses DNA defects to fight drug-resistant tumorson July 28, 2022 at 11:14 am
A new drug uses DNA repair defects to target drug-resistant tumors, such as the most aggressive type of brain cancer, Glioblastoma.
- Potential "Weak Spot" Identified Against Multidrug Resistant Tumorson July 25, 2022 at 3:34 am
Researchers have discovered one of the causes of multidrug resistance in cancers and a potential strategy to combat it. The study shows that mutations that inactivate the gene FBXW7 “reduce the ...
- Scientists identify potential "weak spot" in drug-resistant cancerson July 24, 2022 at 11:41 pm
Scientists in Spain have uncovered a mechanism behind why some cancer patients don’t respond well to treatments – and more importantly, found a “weak spot” that could be targeted by existing drugs.
- A 'weak spot' discovered that potentially makes multi-drug resistant tumors vulnerableon July 22, 2022 at 10:28 am
One of the greatest challenges facing cancer researchers is to understand why some patients don't respond to treatments. In some cases, tumors exhibit what is known as multidrug resistance (MDR), ...
via Bing News